Back to Search Start Over

Assessing the impact of switching to the Tobacco Heating System on cardiovascular disease: Translating basic science into clinical benefit

Authors :
S. Maeder
Christelle Haziza
Blaine Phillips
Patrick Picavet
Annie Heremans
G. de la Bourdonnaye
Julia Hoeng
Frank Luedicke
Gizelle Baker
A. Elamin
Nikolai V. Ivanov
P. Vanschveeuwiijck
Manuel C. Peitsch
C. Goujon
Cam Tuan Tran
Sandrine Pouly
C. Pater
P. Pratte
C. Poussin
Source :
Archives of Cardiovascular Diseases Supplements. 12:202
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Background Cigarette smoke (CS) is causally linked to the development of cardiovascular diseases (CVD). Tobacco harm reduction, by virtue of substituting cigarettes with less harmful products, is a complementary approach to current strategies for smokers who would otherwise continue to smoke. The Tobacco Heating System (THS) 2.2 is a novel tobacco product that heats tobacco instead of burning it, never allowing the temperature to exceed 350 °C, thereby preventing the combustion process from occurring and producing substantially lower levels of toxicants than CS. Objective Philip Morris International's (PMI) assessment program aims to demonstrate that switching to THS has the potential to reduce the risk of smoking-related diseases compared with continued smoking. Methods The program includes in vitro/in vivo toxicology testing methods that follow OECD guidelines and GLP, a systems toxicology approach, and randomized, controlled clinical studies that follow the principles of GCP. Results The results of the THS assessment program demonstrated that cardiovascular toxicants are reduced by an average of > 92% in THS aerosol vs. CS. The effects of THS aerosol on the adhesion of monocytic cells to human coronary endothelial cells in vitro are significantly reduced. Switching to THS halted the progression of CS-induced atherosclerotic changes in ApoE-/- mice in vivo. Biomarkers linked to the development of smoking-related diseases were analyzed following a 6-month randomized, controlled clinical study with THS, which demonstrated a consistent improvement of biomarkers in different mechanistic pathways. Conclusions The evidence available to date indicates that switching to THS has the potential to reduce the risk of smoking-related diseases such as CVD. As a next step, PMI will complement its THS assessment program with cardiovascular outcome studies intended to further support the clinical benefits of switching to THS over continuous smoking.

Details

ISSN :
18786480
Volume :
12
Database :
OpenAIRE
Journal :
Archives of Cardiovascular Diseases Supplements
Accession number :
edsair.doi...........5094be4adf5a46bc70f46b08bcbf13c6
Full Text :
https://doi.org/10.1016/j.acvdsp.2020.03.009